Date: 2013-09-19
Type of information: Private placement
Company: Biomay (Austria)
Investors: existing shareholders
Amount: €5 million
Funding type: private placement and loan
Planned used: The fresh capital will be employed for seamless clinical development of the grass pollen allergy vaccine BM32, and the preclinical evaluation of the pipeline products for house dust mite, cat, ragweed and birch allergies.
Others: * On September 19, 2013, Biomay has announced that the company has completed a private placement with a volume of €3 million. The new shares were subscribed by the group of existing shareholders. In Addition, the company has been awarded a loan with a volume of € 2 million from the ERP loan program, administered by the Austria Wirtschaftsservice GmbH (AWS), the SME business development bank of the Austrian Government.
Therapeutic area: Allergic diseases - Immunological diseases
